FY2028 EPS Forecast for C4 Therapeutics Lowered by Analyst

Key Points

• Analysts at Brookline Capital Management have lowered their FY2028 earnings estimate for C4 Therapeutics to $1.94 per share from a previous estimate of $1.95.
• The company's stock rating was downgraded from "hold" to "sell" by Wall Street Zen.
• C4 Therapeutics reported a quarterly EPS of ($0.37), beating analyst expectations, and had a total revenue of $6.46 million for the quarter.

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Equities research analysts at Brookline Capital Management dropped their FY2028 earnings estimates for C4 Therapeutics in a research report issued on Thursday, August 7th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of $1.94 per share for the year, down from their prior estimate of $1.95. The consensus estimate for C4 Therapeutics' current full-year earnings is ($1.52) per share. Brookline Capital Management also issued estimates for C4 Therapeutics' FY2029 earnings at $22.04 EPS.

Separately, Wall Street Zen lowered shares of C4 Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.

C4 Therapeutics Trading Down 3.1%

Shares of NASDAQ:CCCC opened at $2.50 on Monday. The company has a fifty day simple moving average of $1.84 and a 200 day simple moving average of $2.00. The firm has a market cap of $177.52 million, a PE ratio of -1.58 and a beta of 2.97. C4 Therapeutics has a 12-month low of $1.09 and a 12-month high of $7.22.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.01. The business had revenue of $6.46 million during the quarter, compared to analyst estimates of $5.24 million. C4 Therapeutics had a negative net margin of 325.88% and a negative return on equity of 53.91%.

Hedge Funds Weigh In On C4 Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Savant Capital LLC acquired a new position in C4 Therapeutics in the second quarter worth $38,000. Crestwood Advisors Group LLC acquired a new position in C4 Therapeutics in the second quarter worth $41,000. Y Intercept Hong Kong Ltd acquired a new position in C4 Therapeutics in the second quarter worth $75,000. R Squared Ltd acquired a new position in C4 Therapeutics in the second quarter worth $44,000. Finally, Brookstone Capital Management acquired a new position in C4 Therapeutics in the second quarter worth $42,000. Institutional investors and hedge funds own 78.81% of the company's stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.